Tofacitinib Boxed Warning Revised on FDA Label in 2026

By Hipa.ai Research · August 17, 2026

Synced daily from openFDA and ClinicalTrials.gov. Last sync: August 27, 2026.

The FDA revised the boxed warning on the tofacitinib label effective 17 August 2026. The warning addresses serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The supplied record does not specify the exact wording added, removed, or otherwise changed in the revision.

Background

Tofacitinib is the drug named in the FDA label event. The record also identifies tofacitinib citrate and the brands Xeljanz and Xeljanz XR as associated names. The boxed-warning summary specifically refers to patients treated with tofacitinib extended-release tablets and states that they are at increased risk for developing serious bacterial infections. The supplied data do not provide a mechanism of action, dosing information, approved indications, or prevalence figures.

What changed

The event was classified as an FDA label revision involving the boxed warning. The warning heading lists serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The available summary begins with a statement that patients treated with tofacitinib extended-release tablets are at increased risk for serious bacterial infections, but the supplied text is truncated and does not provide the complete warning.

Drug: tofacitinib
Event: boxed-warning revision
Effective date: 17 August 2026
Listed warning topics: serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis

What this means

Clinicians and medication-information teams should use the revised FDA labeling when reviewing the risks associated with tofacitinib, including its extended-release tablet formulation. The event confirms that the boxed warning covers five serious risk categories, but the supplied record does not establish how the revised language differs from the previous label or provide new event rates, comparative findings, or prescribing recommendations.

Source

Source: FDA, DailyMed drug-label record documenting a boxed-warning revision effective 17 August 2026. The record is available from dailymed.nlm.nih.gov at https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=576722e5-6639-452d-a5c3-33a064f19481.